Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
Yongfeng XuQunli XiongYang YangNingna WengJunjun LiJinlu LiuXiaojuan YangZhu ZengZhiwei ZhangQing ZhuPublished in: Journal of clinical medicine (2022)
Serum NRDC may play a useful diagnostic biomarker to evaluate the aggressive clinical features in PAAD patients.